Journals / Respiratory Case Reports / 2019 / Cilt: 8 - Sayı: 2

Interstitial Lung Disease in Systemic Lupus Erythematosus

Sistemik Lupus Eritematozusta İnterstisyel Akciğer Hastalığı

Pages
40–43
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here we report on two ILD in SLE cases:in one case, ILD was the first sign of SLE; and inanother, ILD appeared after the diagnosis of SLE hadbeen established.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Connective tissue disease (CTD) is one of the etiologies of known-cause interstitial lung disease (ILD) thatis frequently found with systemic sclerosis, rheumatoidarthritis, mixed-CTD and Sjӧgren syndrome, butwhich occurs rarely in systemic lupus erythematosus(SLE) patients.
📊
Key Findings & Data:A diagnosis of ILD in SLE can be challenging, as the physician should first exclude otherpulmonary involvements, including airway disorders,pulmonary infection and vascular abnormality.
💡
Conclusion & Impact:Here we report on two ILD in SLE cases:in one case, ILD was the first sign of SLE; and inanother, ILD appeared after the diagnosis of SLE hadbeen established.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Connective tissue disease (CTD) is one of the etiologies of known-cause interstitial lung disease (ILD) thatis frequently found with systemic sclerosis, rheumatoidarthritis, mixed-CTD and Sjӧgren syndrome, butwhich occurs rarely in systemic lupus erythematosus(SLE) patients. A diagnosis of ILD in SLE can be challenging, as the physician should first exclude otherpulmonary involvements, including airway disorders,pulmonary infection and vascular abnormality. Themanagement of ILD in SLE and other CTDs patientsincludes corticosteroid and other immunosuppressivemedications. Here we report on two ILD in SLE cases:in one case, ILD was the first sign of SLE; and inanother, ILD appeared after the diagnosis of SLE hadbeen established.

Özet

Nedeni bilinen interstisiyel akciğer hastalıklarının (İAH) etyolojilerinden birisi de bağ dokusu hastalıkları (BDH)'dır. Nedeni bilinen İAH’ya yol açana BDH arasında, sistemik skleroz, romatoid artrit, miks bağ dokusu hastalıkları ve Sjögren sendromu sıklıkla bulunmaktadır. Ancak sistemik lupus eritematozus (SLE) hastalarında bu durum nadiren görülür. SLE’de İAH tanısı koymak zordur. Hava yolu hastalıkları, pulmoner infeksiyon ve vasküler anormallikler gibi diğer pulmoner tutulumlar öncelikle ekarte edilmelidir. SLE de ve diğer BDH olan İAH hastalarının tedavisinde kortikosteroidler ve diğer immünsüpressif ilaçlar kullanılır. Burada İAH olan iki SLE olgusu sunulmaktadır. Bir olguda SLE’nin ilk bulgusu İAH idi, diğer olguda SLE tanısından sonra İAH görüldü.

🔖

Cite This Article

Amanda, G., Fathana, P. B., Sutoyo, D. K. (2022). Interstitial Lung Disease in Systemic Lupus Erythematosus. Respiratory Case Reports, Cilt: 8 - Sayı: 2, 40–43. https://ajindex.com/articles/588964

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Maniati M, Borie R, et al. Investigation of lung involvement in connective tissue disorders. Respiration 2015; 90:2-24. [CrossRef] 2. Mittoo S, Fell CD. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2014; 35:249-54. [CrossRef] 3. Fischer A, Brown KK. Interstitial lung disease in undifferentiated forms of connective tissue disease. Arthritis Care Res (Hoboken) 2015; 67:4-11. [CrossRef] 4. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013; 143:814-24. [CrossRef] 5. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther 2010; 12:213. [CrossRef] 6. Fong W, Yoong J. Interstitial lung disease and rheumatoid arthritis: a review. Proceed Singapore Healthcare 2015; 24:35-41. [CrossRef] 7. Demoruelle MK, Mittoo S, Solomon JJ. Connective tissue disease-related interstitial lung disease. Best Pract Res Clin Rheumatol 2016; 30:39-52. [CrossRef] 8. Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial lung disease in the connective tissue diseases. Clin Chest Med 2012; 33:123-49. [CrossRef] 9. Aparicio IJ, Lee JS. Connective tissue disease-associated interstitial lung diseases: unresolved issues. Semin Respir Crit Care Med 2016; 37:468-76. [CrossRef] 10. Henry TS, Little BP, Veeraraghavan S, Bhalla S, Elicker BM. The spectrum of interstitial lung disease in connective tissue disease. J Thorac Imaging 2016; 31:65-77. [CrossRef] 11. Lauretis A, Veeraraghavan S, Renzoni E. Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ? Chronic Respiratory Disease 2011; 8:53-82. [CrossRef] 12. Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Rev Clin Immunol 2016; 12:509-20. [CrossRef] 13. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012; 380:689-98. [CrossRef] 14. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue diseaseassociated interstitial lung disease. J Rheumatol 2013; 40(5):640-6. [CrossRef]